Gilead Sciences, Inc. (GILD)

Gilead Sciences began as a small biotech company with a single idea: design molecules that could interfere with the replication of viruses. The company has now transformed itself across four decades into one of the world’s largest specialty pharmaceutical companies, and its history is a case study in how a business built on breakthrough science can stay relevant only by reinventing itself each time a product matures or a competitive threat emerges.

From antiviral chemistry to HIV medicines

Gilead was founded in 1987 by Michael Riordan, a chemist who saw an opportunity to design antiviral compounds at a time when viruses were killing millions and mainstream pharmaceutical companies had largely abandoned the field as too difficult and too uncertain. The company’s early years were lean, focused on research into nucleoside reverse-transcriptase inhibitors—molecules that could gum up the molecular machinery viruses use to replicate. The science was elegant but arcane, and the company had no products and no clear path to revenue.

That path became clear when the HIV epidemic exploded in the 1980s and 1990s. Gilead developed tenofovir, a molecule that slowed HIV replication, and licensed it to larger pharmaceutical partners who handled the regulatory approval and marketing. The drug was effective, but the real breakthrough came when Gilead combined its antiviral expertise with understanding of how these molecules could be formulated. The company developed fixed-dose combinations—pills that contained multiple antivirals in one tablet, making it easier for patients to take their medicines consistently. This might sound incremental, but it was strategically crucial: adherence to HIV regimens is the difference between a suppressible disease and treatment failure. Pills that required taking fewer tablets per day saved lives and created customer loyalty.

By the late 1990s and early 2000s, Gilead had amassed a portfolio of HIV medicines and the expertise to package them into increasingly convenient regimens. Gilead Atripla (efavirenz, emtricitabine, tenofovir)—three drugs in one pill taken once daily—became a standard treatment and a blockbuster. The company had transformed from a scrappy research lab into a major biopharmaceutical player, with revenues and profits to match.

The hepatitis C pivot

Gilead’s second act came in the 2010s when the company acquired Pharmasset, a smaller biotech company that had developed sofosbuvir, a nucleotide analogue that attacked hepatitis C virus replication at a different point in the viral lifecycle. The acquisition was large and expensive—about twelve billion dollars—but the scientific gamble was that sofosbuvir could be the foundation of a cure for hepatitis C.

That gamble succeeded beyond expectation. Gilead combined sofosbuvir with other antivirals to create regimens that could cure hepatitis C in the majority of patients over twelve weeks of treatment. Sovaldi and then Harvoni became blockbusters virtually overnight. For the first time in the history of infectious disease, a viral infection that had plagued millions—causing cirrhosis, liver cancer, and death—could be cured.

The hepatitis C franchise generated enormous revenues and profits, but it had a structural problem: once you cure someone of hepatitis C, they do not need the medicine anymore. The disease is curable and the population of untreated patients is finite. Gilead moved aggressively to treat as many patients as possible and to expand access in lower-income countries, partly from medical ethics and partly because curing patients maximised the franchise’s total revenue before the market matured.

By the early 2020s, the hepatitis C market had peaked and declined as prevalence fell and the population of treatable patients shrank. Gilead was forced to confront the same problem that had driven its earlier pivot: a blockbuster franchise built on curing an epidemic eventually runs out of patients.

The present structure and new frontiers

Gilead’s current business is more diverse than the HIV and hepatitis C franchises alone. The company has developed treatments for other viral diseases—influenza antivirals, respiratory syncytial virus, and others. It has expanded into immunology and inflammation, acquiring companies like Kite Pharma (cell therapy for cancer) to diversify beyond antivirals. It has also pursued long-acting injectable formulations of its HIV medicines, which patients can receive every two months rather than taking pills daily, a convenience that has appeal for both treatment and prevention.

This portfolio approach reflects a hard-won lesson: biotechnology companies that bet everything on a single blockbuster and do not build a pipeline are always facing a cliff when the blockbuster matures or loses patent protection. Gilead is now more of a diversified specialty pharma company than a pure-play antiviral company, though antivirals remain its core strength and the bulk of its profit.

The company is also investing heavily in oncology and cell therapy, areas where Gilead has less historical expertise but sees large markets and the potential for new franchises. This expansion into areas beyond infectious disease is risky—Gilead will be competing against larger, more diversified rivals—but necessary because the core viral-disease markets are finite and maturing.

The pressures of patenting and generic competition

Gilead’s fortunes are tethered to its patent portfolio. As patents expire on blockbuster antivirals, generic manufacturers can enter the market and prices collapse. This is especially acute in HIV, where the disease burden is heaviest in low-income countries that are both sensitive to price and large in volume. Gilead has tried to manage this by developing new formulations—long-acting injectables, combinations of existing drugs—that extend patent protection. But the underlying economics of HIV are shifting toward lower prices globally, compressing margins.

A second pressure is the question of how aggressively Gilead prices its medicines in the context of public health. Gilead drew fierce criticism in 2011 for the price of Sovaldi, which cost about one thousand dollars per pill—over ninety thousand dollars for a course of treatment—despite the fact that the drug’s development was subsidized by government research funding and that Pharmasset’s previous investors had paid far less to acquire the company. The company eventually negotiated lower prices in many markets and licensed generic production in India and elsewhere, but the episode revealed the tension between maximising profits and meeting ethical obligations.

The pipeline and the outlook

Gilead’s future depends on whether it can sustain revenue and profit as its legacy antivirals mature and as it builds new franchises in cell therapy, immunology, and oncology. The company is investing billions in research and development, but biotech is inherently uncertain—drugs fail in trials, clinical candidates prove toxic or ineffective, and competitors may reach the market first with better solutions.

One strategic question is whether Gilead will make transformational acquisitions (as it did with Pharmasset) or try to build internally. Large acquisitions carry integration risk but can rapidly add pipeline assets. Internal development is slower but preserves culture and avoids the overpayment that often characterises biotech M&A.

A second question is how Gilead will navigate the shift toward prevention in HIV. If prevention regimens (like long-acting injectable cabotegravir and rilpivirine) become the standard of care, the revenue will be enormous but the patient population treated for active infection will shrink, changing the economics of the existing franchise.

Researching Gilead

Anyone studying Gilead should begin with the annual 10-K filing (SEC CIK 0000882095), which details the revenue contribution from each drug, the patent expiration schedule, and the pipeline. The earnings calls reveal management’s commentary on patient uptake of new formulations, the pace of generic competition in key markets, and the trajectory of the pipeline.

Key metrics to track include revenue from legacy HIV and hepatitis C franchises (watching for cliff declines), uptake of next-generation formulations, and the progress of pipeline assets in trials. Because Gilead is now diversified across multiple therapeutic areas, understanding which franchises are growing and which are contracting is essential to evaluating the company’s direction.